Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cosmina-Gabriela Duta-Bratu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting PAK1 Within Group I PAKs: Current Challenges and Pharmacological Perspectives

    by George Nicolae Daniel Ion, Cosmina Gabriela Duta-Bratu, Dragos Paul Mihai, George Mihai Nitulescu

    The p21-activated kinase 1 (PAK1) has been investigated as a therapeutic target for more than two decades, particularly in cancer, where it contributes to cytoskeletal regulation, proliferation, survival, migration and therapy resistance. Despite the development of numerous potent inhibitors, selective pharmacological modulation of PAK1 remains difficult because of the high similarity of the group I PAK catalytic domains, especially PAK1 and PAK2, together with differences in conformational state, cellular localization and kinase-independent functions. This review examines PAK1 within the broader PAK kinase family and critically evaluates the principal pharmacological strategies developed to modulate its activity, including ATP-competitive and allosteric inhibition, targeted degradation, polypharmacology, combination therapies and indirect approaches. Recent structural studies indicate that local conformational differences between PAK1 and PAK2 can be exploited for improved isoform discrimination, while PAK1-selective degraders provide an alternative means of affecting both catalytic and non-catalytic functions. A snapshot analysis of current ChEMBL bioactivity data further shows that, although numerous compounds display high reported potency against PAK1, matched quantitative information for PAK2 and PAK3 is available for only a limited subset, leaving isoform selectivity unresolved for most compounds. Recent findings also position PAK1 within adaptive and treatment-resistance signaling rather than as a universal oncogenic dependency. Future progress will therefore depend not only on improving compound potency, but on integrating isoform profiling, cellular target engagement, structural information and disease-specific biomarkers to identify the settings in which PAK1 modulation can provide a meaningful therapeutic advantage.

  • Open Access

    Development of Photoprotective Cosmetic Formulations Containing Salix × fragilis Extracts: Phytochemical Characterization, Biological Activity, and In Vitro SPF Evaluation

    by Alexandra Mihaela Pasitoniu, Georgiana Nitulescu, Cerasela Elena Gird, Cosmina-Gabriela Duta-Bratu, Valentina-Andreea Calmuc, Stefania-Adelina Milea, George Mihai Nitulescu, Emanuela-Alice Luta, Dumitru Lupuliasa, Corina Andrei, et al.

    Salix × fragilis represents a promising botanical source of phenolic compounds with potential applications in photoprotective cosmetics. The present study investigated aqueous (SFw), hydroethanolic (SFhe), and ethanolic (SFe) extracts regarding their phytochemical composition, antioxidant activity, safety profile, photoprotective potential, and applicability in topical formulations. Total phenolic and flavonoid contents were determined spectrophotometrically, while phytochemical profiling was performed by FT-IR and UHPLC–HRMS. Antioxidant activity was evaluated using DPPH, ABTS, and CUPRAC assays. Potential toxicity was preliminarily assessed using Daphnia magna acute and embryo toxicity assays as an alternative screening model for early safety evaluation. Photoprotective activity was estimated by the Mansur spectrophotometric method, and finally, selected extracts were incorporated into cosmetic formulations, followed by physicochemical characterization and in vitro SPF determination. The hydroethanolic extract exhibited the highest phenolic content and antioxidant activity, whereas the ethanolic extract showed the greatest photoprotective capacity, reaching an SPF of 70.0 at 2.0 mg/mL. The investigated extracts exhibited a favorable preliminary safety profile in the Daphnia magna model, with only the hydroethanolic extract producing a measurable 48 h LC50 (576.5 μg/mL), whereas no evident embryotoxic or teratogenic effects were observed, supporting their further investigation using complementary safety models. Selected extracts were successfully incorporated into cosmetic formulations, which were subsequently physicochemically characterized. Incorporation of the ethanolic extract increased the SPF of the UV filter-containing formulation from 25.82 to 30.01 (approximately 16%).

  • Open Access

    Inhibitory Effects on Staphylococcus aureus Sortase A by Aesculus sp. Extracts and Their Toxicity Evaluation

    by Octavian Tudorel Olaru, George Mihai Nitulescu, Andreea Miruna Codreanu, Valentina-Andreea Calmuc, Luanne Venables, Maryna van de Venter, Cerasela Elena Gird, Cosmina-Gabriela Duta-Bratu, Georgiana Nitulescu

    A promising strategy for combating bacterial infections involves the development of agents that disarm the virulence factors of pathogenic bacteria, thereby reducing their pathogenicity without inducing direct lethality. Sortase A, a crucial enzyme responsible for anchoring virulence factors to the cell surface of several pathogenic bacteria, has emerged as a possible target for antivirulence strategies. A series of hippocastanum species (Aesculus pavia, A. parviflora, Aesculus x carnea, and A. hippocastanum) were used to prepare ethanol- and water-based extracts for assessing their effect on Staphylococcus aureus sortase A. The extracts were characterized through HPLC analysis, and their polyphenols content was determined using the Folin–Ciocalteu method. The specific toxicity profile was evaluated in Daphnia magna using the median lethal concentration (LC50) and against the fibroblast MRHF cell line. The half maximal inhibitory concentration (IC50) values on sortase A, determined after 30 min of incubation, ranged from 82.70 to 304.31 µg/mL, with the A. pavia water extract exhibiting the highest inhibitory effect. The assessment of the A. pavia water extract on human fibroblasts revealed no significant signs of toxicity, even at a concentration of 500 µg/mL. This reduced toxicity was further validated through the Daphnia assay. These findings highlight the low toxicity and the potential of this extract as a promising source of future development of bacteria antivirulence solutions.


  • Open Access

    Resveratrol and Other Natural Oligomeric Stilbenoid Compounds and Their Therapeutic Applications

    by Cosmina-Gabriela Duta-Bratu, George Mihai Nitulescu, Dragos Paul Mihai, Octavian Tudorel Olaru

    The use of natural compounds as an alternative to synthetic molecules has become a significant subject of interest in recent decades. Stilbenoids are a group of phenolic compounds found in many plant species and they have recently gained the focus of a multitude of studies in medicine and chemistry, resveratrol being the most representative molecule. In this review, we focused on the research that illustrates the therapeutic potential of this class of natural molecules considering various diseases with higher incidence rates. PubChem database was searched for bioactivities of natural stilbenoids, while several keywords (i.e., “stilbenoids”, “stilbenoid anticancer”) were used to query PubMed database for relevant studies. The diversity and the simplicity of stilbenes’ chemical structures together with the numerous biological sources are key elements that can simplify both the isolation of these compounds and the drug design of novel bioactive molecules. Resveratrol and other related compounds are heterogeneously distributed in plants and are mainly found in grapes and wine. Natural stilbenes were shown to possess a wide range of biological activities, such as antioxidant, anti-inflammatory, antihyperglycemic, cardioprotective, neuroprotective, and antineoplastic properties. While resveratrol is widely investigated for its benefits in various disorders, further studies are warranted to properly harness the therapeutic potential of less popular stilbenoid compounds.


  • Top Cited Papers
    Open Access

    The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies

    by George Mihai Nitulescu, Gheorghe Stancov, Oana Cristina Seremet, Georgiana Nitulescu, Dragos Paul Mihai, Cosmina Gabriela Duta-Bratu, Stefania Felicia Barbuceanu, Octavian Tudorel Olaru

    The altered activation or overexpression of protein kinases (PKs) is a major subject of research in oncology and their inhibition using small molecules, protein kinases inhibitors (PKI) is the best available option for the cure of cancer. The pyrazole ring is extensively employed in the field of medicinal chemistry and drug development strategies, playing a vital role as a fundamental framework in the structure of various PKIs. This scaffold holds major importance and is considered a privileged structure based on its synthetic accessibility, drug-like properties, and its versatile bioisosteric replacement function. It has proven to play a key role in many PKI, such as the inhibitors of Akt, Aurora kinases, MAPK, B-raf, JAK, Bcr-Abl, c-Met, PDGFR, FGFRT, and RET. Of the 74 small molecule PKI approved by the US FDA, 8 contain a pyrazole ring: Avapritinib, Asciminib, Crizotinib, Encorafenib, Erdafitinib, Pralsetinib, Pirtobrutinib, and Ruxolitinib. The focus of this review is on the importance of the unfused pyrazole ring within the clinically tested PKI and on the additional required elements of their chemical structures. Related important pyrazole fused scaffolds like indazole, pyrrolo[1,2-b]pyrazole, pyrazolo[4,3-b]pyridine, pyrazolo[1,5-a]pyrimidine, or pyrazolo[3,4-d]pyrimidine are beyond the subject of this work.